Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin

被引:71
|
作者
McDonell, Laura M. [1 ]
Kernohan, Kristin D. [1 ]
Boycott, Kym M. [1 ]
Sawyer, Sarah L. [1 ]
机构
[1] Univ Ottawa, Childrens Hosp Eastern Ontario, Res Inst, Dept Genet, Ottawa, ON K1H 8L1, Canada
基金
加拿大健康研究院;
关键词
GROWTH-FACTOR RECEPTOR-3; ACTIVATING MUTATIONS; PASSENGER MUTATIONS; MISSENSE MUTATIONS; FGFR2; MUTATIONS; APERT-SYNDROME; LADD SYNDROME; DISORDERS; PHENOTYPE; CARCINOMA;
D O I
10.1093/hmg/ddv254
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Receptor tyrosine kinases (RTKs) are a family of ligand-binding cell surface receptors that regulate a wide range of essential cellular activities, including proliferation, differentiation, cell-cycle progression, survival and apoptosis. As such, these proteins play an important role during development and throughout life; germline mutations in genes encoding RTKs cause several developmental syndromes, while somatic alterations contribute to the pathogenesis of many aggressive cancers. This creates an interesting paradigm in which mutation timing, type and location in a gene leads to different cell signaling and biological responses, and ultimately phenotypic outcomes. In this review, we highlight the roles of RTKs in developmental disorders and cancer. The multifaceted roles of these receptors, their genetic signatures and their signaling during developmental morphogenesis and oncogenesis are discussed. Additionally, we propose that comparative analysis of RTK mutations responsible for developmental syndromes may shed light on those driving tumorigenesis.
引用
收藏
页码:R60 / R66
页数:7
相关论文
共 50 条
  • [41] Estrogen Receptor β Is Involved in Acquired Resistance to EGFR-tyrosine Kinase Inhibitors in Lung Cancer
    Sugiura, Hiroki
    Miki, Yasuhiro
    Iwabuchi, Erina
    Saito, Ryoko
    Ono, Katsuhiko
    Sato, Ikuro
    Okada, Yoshinori
    Sasano, Hironobu
    ANTICANCER RESEARCH, 2021, 41 (05) : 2371 - 2381
  • [42] Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis
    Saleh, Ramy R.
    Fuentes Antras, Jesus
    Peinado, Paloma
    Perez-Segura, Pedro
    Pandiella, Atanasio
    Amir, Eitan
    Ocana, Alberto
    CANCER TREATMENT REVIEWS, 2019, 77 : 11 - 19
  • [43] Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
    Wu, Jenn-Yu
    Shih, Jin-Yuan
    ONCOTARGETS AND THERAPY, 2016, 9 : 6137 - 6145
  • [44] The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer
    Griffin, Nathan
    Marsland, Mark
    Roselli, Severine
    Oldmeadow, Christopher
    Attia, John
    Walker, Marjorie M.
    Hondermarck, Hubert
    Faulkner, Sam
    BIOMOLECULES, 2020, 10 (09) : 1 - 13
  • [45] A systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer
    Shen, Xiaokun
    Chen, Beibei
    Ma, Zhaosheng
    Xie, Bojian
    Cao, Xinguang
    Yang, Tiejun
    Zhao, Yuzhou
    Qin, Jianjun
    Li, Jicheng
    Cao, Feilin
    Chen, Xiaobing
    JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, 2016, 36 (01) : 89 - 97
  • [46] Oncogenic potential is related to activating effect of cancer single and double somatic mutations in receptor tyrosine kinases
    Hashimoto, Kosuke
    Rogozin, Igor B.
    Panchenko, Anna R.
    HUMAN MUTATION, 2012, 33 (11) : 1566 - 1575
  • [47] Two mutations in the same low-density lipoprotein receptor allele act in synergy to reduce receptor function in heterozygous familial hypercholesterolemia
    Jensen, HK
    Jensen, TG
    Faergeman, O
    Jensen, LG
    Andresen, BS
    Corydon, MJ
    Andreasen, PH
    Hansen, PS
    Heath, F
    Bolund, L
    Gregersen, N
    HUMAN MUTATION, 1997, 9 (05) : 437 - 444
  • [48] Validation of a Phosphoprotein Array Assay for Characterization of Human Tyrosine Kinase Receptor Downstream Signaling in Breast Cancer
    Chergui, Fadila
    Chretien, Anne-Sophie
    Bouali, Sanae
    Ramacci, Carole
    Rouyer, Marie
    Bastogne, Thierry
    Genin, Pascal
    Leroux, Agnes
    Merlin, Jean-Louis
    CLINICAL CHEMISTRY, 2009, 55 (07) : 1327 - 1336
  • [49] Evidence for 2-Methoxyestradiol-Mediated Inhibition of Receptor Tyrosine Kinase RON in the Management of Prostate Cancer
    Batth, Izhar Singh
    Huang, Shih-Bo
    Villarreal, Michelle
    Gong, Jingjing
    Chakravarthy, Divya
    Keppler, Brian
    Jayamohan, Sridharan
    Osmulski, Pawel
    Xie, Jianping
    Rivas, Paul
    Bedolla, Roble
    Liss, Michael A.
    Yeh, I-Tien
    Reddick, Robert
    Miyamoto, Hiroshi
    Ghosh, Rita
    Kumar, Addanki P.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (04) : 1 - 18
  • [50] A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinoma cancer without indication for chemotherapy
    Zheng, Xiao
    Liu, Guan
    Wang, Shengye
    Zhang, Yunli
    Bao, Wenlong
    Deng, Dehou
    Mao, Weiming
    Fang, Meiyu
    ONCOLOGY LETTERS, 2014, 8 (04) : 1563 - 1566